Industry Finds Little to Like in Biosimilars Draft Guidance

Generic Line
The FDA’s newly created four-point sliding scale of comparability between original biologic products and their biosimilars does not belong in guidance on data to demonstrate that similarity, PhRMA says.

To View This Article:


Subscribe To Generic Line

Buy This Article Now

Add this article to your cart for $40.00